The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Elias Jabbour, MD, and Dennis Kim, MD, discuss data for recent olverembatininb and its place in CML management.

Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.

D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.

The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.

Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.

MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses first-line efficacy data for divarasib plus pembrolizumab in KRAS G12C+ NSCLC from the KRASCENDO-170 study.

ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

The CD70-targeting CAR T cell therapy, ALLO-316, demonstrated encouraging results in previously treated patients with advanced ccRCC.

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

Shubham Pant, MD, MBBS, discusses data for daraxonrasib and its potential impact on pancreatic cancer management.

High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.

Elias Jabbour, MD, discusses the significance of the FDA approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.

Seventy percent of patients with B-cell ALL had residual levels of cancer cells eliminated during treatment with inotuzumab ozogamicin.

This episode highlights Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development.